A Multicenter, Randomized, Double-Blind, Actively-Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3 g Bid Versus Mesalamine (5-ASA) as Asacol 0.8 g Tid in Mildly to Moderately Active Ulcerative Colitis

Trial Profile

A Multicenter, Randomized, Double-Blind, Actively-Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3 g Bid Versus Mesalamine (5-ASA) as Asacol 0.8 g Tid in Mildly to Moderately Active Ulcerative Colitis

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Balsalazide (Primary) ; Mesalazine
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Valeant Pharmaceuticals International
  • Most Recent Events

    • 20 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top